Patents by Inventor Daniel P. Silver

Daniel P. Silver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for predicting anti-cancer response
    Patent number: 10577662
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: March 3, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., Children's Medical Center Corporation, The Technical University of Denmark
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • Oncogene associated with human cancers and methods of use thereof
    Patent number: 9874565
    Abstract: The present invention provides methods of treating cancer by inhibiting MECP2 and identifying cancers that will respond to therapy using MECP2 as a biomarker.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: January 23, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Daniel P. Silver, Manish Neupane, David E. Hill
  • METHODS FOR PREDICTING ANTI-CANCER RESPONSE
    Publication number: 20170037478
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Application
    Filed: October 20, 2016
    Publication date: February 9, 2017
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC., CHILDREN'S MEDICAL CENTER CORPORATION, THE TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • Methods for predicting anti-cancer response
    Patent number: 9512485
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: December 6, 2016
    Assignees: Dana-Farber Cancer Institute. Inc., The Brigham and Women's Hospital. Inc., Children's Medical Center Corporation, The Technical University of Denmark
    Inventors: Andrea L. Richardson, Zhigang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • ONCOGENE ASSOCIATED WITH HUMAN CANCERS AND METHODS OF USE THEREOF
    Publication number: 20160139127
    Abstract: The present invention provides methods of treating cancer by inhibiting MECP2 and identifying cancers that will respond to therapy using MECP2 as a biomarker.
    Type: Application
    Filed: June 23, 2014
    Publication date: May 19, 2016
    Inventors: Daniel P. Silver, Manish Neupane, David E. Hill
  • METHODS FOR PREDICTING ANTI-CANCER RESPONSE
    Publication number: 20130281312
    Abstract: The present invention is based, in part, on the identification of novel methods for defining predictive biomarkers of response to anti-cancer drugs.
    Type: Application
    Filed: August 19, 2011
    Publication date: October 24, 2013
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE TECHNICAL UNIVERSITY OF DENMARK, CHILDREN'S MEDICAL CENTER CORPORATION, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Andrea L. Richardson, Zhingang C. Wang, Daniel P. Silver, Zoltan Szallasi, Nicolai Juul Birkbak, Aron Charles Eklund
  • Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
    Patent number: 6852530
    Abstract: Nucleic acid molecules comprising at least a first signal site and a recombinase gene operably linked to an expression control sequence, such that upon entry into a cell, there is a first signal site and a second signal site positioned to mediate excision of a sufficient portion of either the recombinase gene or the expression control sequence to extinguish recombinase activity when the first and second signal sites are contacted with a recombinase, cells, transgenics and uses of the foregoing.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: February 8, 2005
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventors: Daniel P. Silver, David M. Livingston
  • Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
    Publication number: 20040231006
    Abstract: Nucleic acid molecules comprising at least a first signal site and a recombinase gene operably linked to an expression control sequence, such that upon entry into a cell, there is a first signal site and a second signal site positioned to mediate excision of a suffcient portion of either the recombinase gene or the expression control sequence to extinguish recombinase activity when the first and second signal sites are contacted with a recombinase, cells, transgenics and uses of the foregoing.
    Type: Application
    Filed: February 26, 2004
    Publication date: November 18, 2004
    Inventors: Daniel P. Silver, David M. Livingston
  • Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
    Publication number: 20020062489
    Abstract: Nucleic acid molecules comprising at least a first signal site and a recombinase gene operably linked to an expression control sequence, such that upon entry into a cell, there is a first signal site and a second signal site positioned to mediate excision of a suffcient portion of either the recombinase gene or the expression control sequence to extinguish recombinase activity when the first and second signal sites are contacted with a recombinase, cells, transgenics and uses of the foregoing.
    Type: Application
    Filed: April 12, 2001
    Publication date: May 23, 2002
    Inventors: Daniel P. Silver, David M. Livingston